Euclidean Capital LLC: PMV PHARMACEUTICALS INC (PMVP): Quarterly 13F Position History
As of Q1 2026, Euclidean Capital LLC reported 2,627,643 shares of PMV PHARMACEUTICALS INC (PMVP), worth $3.3M and representing 0.8% of its 13F equity book. The position first appeared in Q4 2020 and has been disclosed across 22 13F-HR filings in Pactolio's tracked window.
- 2,627,643Shares Held (Latest Filing)
- $3.3MReported Market Value (Latest Filing)
- 0.8%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$26.3KQuarter-over-Quarter Value Change
- 4,179,416Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 22 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 2,627,643 | 0 | — | $3.3M | 0.8% | $1.2 |
| Q4 2025 | 2,627,643 | 0 | — | $3.3M | 0.9% | $1.3 |
| Q3 2025 | 2,627,643 | 0 | — | $3.7M | 1.5% | $1.4 |
| Q2 2025 | 2,627,643 | 0 | — | $2.8M | 0.9% | $1.1 |
| Q1 2025 | 2,627,643 | 0 | — | $2.9M | 1.1% | $1.1 |
| Q4 2024 | 2,627,643 | 0 | — | $4.0M | 0.5% | $1.5 |
| Q3 2024 | 2,627,643 | 0 | — | $3.9M | 0.4% | $1.5 |
| Q2 2024 | 2,627,643 | 0 | — | $4.3M | 0.5% | $1.6 |
| Q1 2024 | 2,627,643 | 0 | — | $4.5M | 0.6% | $1.7 |
| Q4 2023 | 2,627,643 | 0 | — | $8.1M | 0.9% | $3.1 |
| Q3 2023 | 2,627,643 | +82,401 | +3.2% | $16.1M | 3.5% | $6.1 |
| Q2 2023 | 2,545,242 | +208,333 | +8.9% | $15.9M | 4.1% | $6.3 |
| Q1 2023 | 2,336,909 | 0 | — | $11.1M | 9.8% | $4.8 |
| Q4 2022 | 2,336,909 | 0 | — | $20.3M | 19.0% | $8.7 |
| Q3 2022 | 2,336,909 | 0 | — | $27.8M | 25.8% | $11.9 |
| Q2 2022 | 2,336,909 | 0 | — | $33.3M | 28.3% | $14.3 |
| Q1 2022 | 2,336,909 | 0 | — | $48.7M | 28.3% | $20.8 |
| Q4 2021 | 2,336,909 | 432,904 | -15.6% | $54.0M | 30.7% | $23.1 |
| Q3 2021 | 2,769,813 | 1,138,864 | -29.1% | $82.5M | 40.1% | $29.8 |
| Q2 2021 | 3,908,677 | 270,739 | -6.5% | $133.5M | 31.2% | $34.2 |
| Q1 2021 | 4,179,416 | 0 | — | $137.5M | 46.0% | $32.9 |
| Q4 2020 | 4,179,416 | — | — | $257.1M | 54.4% | $61.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Euclidean Capital LLC first disclose a PMVP position in 13F-HR filings?
Euclidean Capital LLC first reported PMV PHARMACEUTICALS INC (PMVP) on its 13F-HR filing for the period ending 2020-12-31 (Q4 2020). The position has appeared on 22 reported quarters within Pactolio's tracked window.
What was Euclidean Capital LLC's most recent quarter-over-quarter share-count change in PMVP?
Euclidean Capital LLC held the same 2,627,643 shares of PMVP between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Euclidean Capital LLC's cost basis in PMVP?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.